Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Remaxol
- Development stage
- Phase 3
- Lead developer
- POLYSAN
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Remaxol is a multicomponent metabolic hepatoprotector developed by POLYSAN. Formulated as a solution for intravenous infusion, it contains a combination of succinic acid, inosine, nicotinamide, methionine, and meglumine. The drug exerts antioxidant, antihypoxic, and hepatoprotective effects by stimulating the activity of antioxidant enzymes and restoring energy metabolism within hepatocytes. It is primarily indicated for the treatment of liver dysfunction associated with acute or chronic damage, including intrahepatic cholestasis, drug-induced liver injury (particularly during cancer chemotherapy), and malignant mechanical jaundice. By stabilizing hepatocyte membranes and reducing hyperbilirubinemia and transaminase levels, Remaxol supports liver recovery and function in patients with chronic diffuse liver diseases.
- Brand names
- Remaxol
- Other names
- inosine + meglumine + methionine + nicotinamide + succinic acid
02
Targets
NAD+/NADH (Nicotinamide adenine dinucleotide (NAD+/NADH) redox system)NAD (Nicotinamide adenine dinucleotide)SDH (Mitochondrial electron transport chain complex II)
Beyond the preview
Go deeper on Remaxol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Remaxol.